How to buy IQVIA shares

Own IQVIA shares in just a few minutes.

Picture not described

We’re reader-supported and may be paid when you visit links to partner sites. We don’t compare all products in the market, but we’re working on it!

IQVIA Holdings Inc (IQV) is a leading diagnostics & research business with stocks listed in the US. It opened the day at US$244.65 after a previous close of US$246.3. During the day the price has varied from a low of USD238.99 to a high of USD247.06. The latest price was USD239.66 (25 minute delay). IQVIA is listed on the NYSE. All prices are listed in US Dollars.

How to buy shares in IQVIA

  1. Compare share trading platforms. To buy shares in a US company from Australia you'll need to find a trading platform that offers access to US stock markets. If you're just starting out, look for a platform with low brokerage and foreign exchange fees.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and tax file number. Fund your account with a bank transfer, credit card or debit card.
  3. Search for IQVIA. Find the share by name or ticker symbol: IQV. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until IQVIA reaches your desired price. To spread out your risk, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. At last close price of US$233.84, weigh your budget against a diversified portfolio that can minimise risk through the market's ups and downs. You may be able to buy a fractional share of IQVIA, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of IQVIA. Optimise your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

IQVIA share price

Use our graph to track the performance of IQV stocks over time.

IQVIA shares at a glance

Information last updated 2021-06-18.
OpenUS$244.65
HighUS$247.06
LowUS$238.99
CloseUS$239.66
Previous closeUS$246.3
Change US$-6.64
Change % -2.6959%
Volume 3,403,030
Information last updated 2021-06-17.
52-week rangeUS$133.18 - US$248.74
50-day moving average US$236.1872
200-day moving average US$201.0789
Target priceUS$258.89
PE ratio 116.8857
Dividend yield N/A (0%)
Earnings per share (TTM) US$2.1

Compare share trading platforms to buy stock

Name Product Standard brokerage for US shares Inactivity fee Currency conversion fee Markets
eToro (US, EU stock trading)
US$0
US$10 per month if there’s been no login for 12 months
0.50%
Global shares, US shares, ETFs
Zero brokerage share trading on US stocks with trades as low as $50.
Join the world’s biggest social trading network when you trade stocks, commodities and currencies from the one account.
IG Share Trading
Finder Award
IG Share Trading
US$0
$50 per quarter if you make fewer than three trades in that period
0.70%
ASX shares, Global shares
$0 brokerage for US and global shares plus get an active trader discount of $5 commission on Australian shares.
Enjoy some of the lowest brokerage fees on the market when trading Australian shares, international shares, plus get access to 24-hour customer support.
Saxo Capital Markets (Classic account)
US$9.9
No
0.75%
ASX shares, Global shares, Forex, CFDs, Margin trading, Options trading, ETFs
Acess 19,000+ stocks on 37 exchanges worldwide
Low fees for Australian and global share trading, no inactivity fees, low currency conversion fee and optimised for mobile.
CMC Markets Stockbroking
US$0
No
0.60%
ASX shares, Global shares, mFunds, ETFs
$0 brokerage on global shares including US, UK and Japan markets.
Trade up to 9,000 products, including shares, ETFs and managed funds, plus access up to 15 major global and Australian stock exchanges.
loading

Compare up to 4 providers

The value of your investments can fall as well as rise and you may get back less than you invested. Past performance is no indication of future results.

Is it a good time to buy IQVIA stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

IQVIA price performance over time

Historical closes compared with the last close of $239.66

1 week (2021-06-14) -1.97%
1 month (2021-05-21) 0.29%
3 months (2021-03-19) 27.26%
6 months (2020-12-18) 32.86%
1 year (2020-06-19) 76.12%
2 years (2019-06-20) 55.10%
3 years (2018-06-20) 126.93%
5 years (2016-06-20) 276.29%

Is IQVIA under- or over-valued?

Valuing IQVIA stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of IQVIA's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

IQVIA's P/E ratio

IQVIA's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 117x. In other words, IQVIA shares trade at around 117x recent earnings.

That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.

IQVIA's PEG ratio

IQVIA's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 1.3098. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.

The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into IQVIA's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.

IQVIA's EBITDA

IQVIA's EBITDA (earnings before interest, taxes, depreciation and amortisation) is US$2 billion.

The EBITDA is a measure of a IQVIA's overall financial performance and is widely used to measure a its profitability.

IQVIA financials

Revenue TTM US$12 billion
Operating margin TTM 7.94%
Gross profit TTM US$3.9 billion
Return on assets TTM 2.51%
Return on equity TTM 7.21%
Profit margin 3.4%
Book value 31.07
Market capitalisation US$47 billion

TTM: trailing 12 months

Shorting IQVIA shares

There are currently 3.0 million IQVIA shares held short by investors – that's known as IQVIA's "short interest". This figure is 16.4% up from 2.6 million last month.

There are a few different ways that this level of interest in shorting IQVIA shares can be evaluated.

IQVIA's "short interest ratio" (SIR)

IQVIA's "short interest ratio" (SIR) is the quantity of IQVIA shares currently shorted divided by the average quantity of IQVIA shares traded daily (recently around 993878.26086957). IQVIA's SIR currently stands at 2.99. In other words for every 100,000 IQVIA shares traded daily on the market, roughly 2990 shares are currently held short.

However IQVIA's short interest can also be evaluated against the total number of IQVIA shares, or, against the total number of tradable IQVIA shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case IQVIA's short interest could be expressed as 0.02% of the outstanding shares (for every 100,000 IQVIA shares in existence, roughly 20 shares are currently held short) or 0.0156% of the tradable shares (for every 100,000 tradable IQVIA shares, roughly 16 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against IQVIA.

Find out more about how you can short IQVIA stock.

IQVIA's environmental, social and governance track record

Environmental, social and governance (known as ESG) criteria are a set of three factors used to measure the sustainability and social impact of companies like IQVIA.

When it comes to ESG scores, lower is better, and lower scores are generally associated with lower risk for would-be investors.

IQVIA's total ESG risk score

Total ESG risk: 26.81

Socially conscious investors use ESG scores to screen how an investment aligns with their worldview, and IQVIA's overall score of 26.81 (as at 12/31/2018) is pretty good – landing it in it in the 37th percentile of companies rated in the same sector.

ESG scores are increasingly used to estimate the level of risk a company like IQVIA is exposed to within the areas of "environmental" (carbon footprint, resource use etc.), "social" (health and safety, human rights etc.), and "governance" (anti-corruption, tax transparency etc.).

IQVIA's environmental score

Environmental score: 1.17/100

IQVIA's environmental score of 1.17 puts it squarely in the 3rd percentile of companies rated in the same sector. This could suggest that IQVIA is a leader in its sector terms of its environmental impact, and exposed to a lower level of risk.

IQVIA's social score

Social score: 14.76/100

IQVIA's social score of 14.76 puts it squarely in the 3rd percentile of companies rated in the same sector. This could suggest that IQVIA is a leader in its sector when it comes to taking good care of its workforce and the communities it impacts.

IQVIA's governance score

Governance score: 6.88/100

IQVIA's governance score puts it squarely in the 3rd percentile of companies rated in the same sector. That could suggest that IQVIA is a leader in its sector when it comes to responsible management and strategy, and exposed to a lower level of risk.

IQVIA's controversy score

Controversy score: 1/5

ESG scores also evaluate any incidences of controversy that a company has been involved in. IQVIA scored a 1 out of 5 for controversy – the highest score possible, reflecting that IQVIA has managed to keep its nose clean.

Environmental, social, and governance (ESG) summary

IQVIA Holdings Inc was last rated for ESG on: 2019-01-01.

Total ESG score 26.81
Total ESG percentile 36.72
Environmental score 1.17
Environmental score percentile 3
Social score 14.76
Social score percentile 3
Governance score 6.88
Governance score percentile 3
Level of controversy 1

IQVIA share dividends

We're not expecting IQVIA to pay a dividend over the next 12 months.

IQVIA share price volatility

Over the last 12 months, IQVIA's shares have ranged in value from as little as US$133.18 up to US$248.74. A popular way to gauge a stock's volatility is its "beta".

IQV.US volatility(beta: 1.46)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NYSE average) beta is 1, while IQVIA's is 1.4576. This would suggest that IQVIA's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

IQVIA overview

IQVIA Holdings Inc. provides advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment offers a range of cloud-based applications and related implementation services; real world solutions that enable life sciences and provider customers to generate and disseminate evidence, which informs health care decision making and improves patients' outcomes; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services. This segment also provides country level performance metrics related to sales of pharmaceutical products, prescribing trends, medical treatment, and promotional activity across various channels, including retail, hospital, and mail order; and measurement of sales or prescribing activity at the regional, zip code, and individual prescriber level. The Research & Development Solutions segment offers project management and clinical monitoring; clinical trial support; virtual trials; and strategic planning and design services, as well as central laboratory, genomic, bioanalytical, ADME, discovery, and vaccine and biomarker laboratory services. The Contract Sales & Medical Solutions segment provides health care provider and patient engagement services, and scientific strategy and medical affairs services. It serves pharmaceutical, biotechnology, device and diagnostic, and consumer health companies. The company was formerly known as Quintiles IMS Holdings, Inc. and changed its name to IQVIA Holdings Inc. in November 2017. IQVIA Holdings Inc. was founded in 1982 and is headquartered in Durham, North Carolina.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on finder.com.au:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com.au is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder only provides general advice and factual information, so consider your own circumstances, or seek advice before you decide to act on our content. By submitting a question, you're accepting our Terms of Use, Disclaimer & Privacy Policy and Privacy & Cookies Policy.
Go to site
Not sure what platform to go with?
Take this quick quiz to find the right share trading platform